Profile
APUS ZTS TAK HLN TEVA NBIX
Company Name Apimeds Pharmaceuticals US, Inc Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $26.14M $67.90B $47.69B $43.90B $22.86B $14.30B
Employees 0.00K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Erik C. Emerson Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
APUS ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 3 3 3 1 4
Quant Rating Sell Neutral Neutral Neutral Strong Sell Buy
Trading
APUS ZTS TAK HLN TEVA NBIX
Last Close $2.08 $148.2 $15.1 $9.81 $19.93 $141.87
High 52 $2.27 $196.48 $15.52 $11.41 $22.77 $153.29
Low 52 - $144.45 $12.89 $9.01 $12.82 $87.59
Price vs. 52 Week High -8.37 % -24.57 % -2.71 % -14.02 % -12.47 % -7.45 %
Price vs. 52 Week Low 0 % 2.6 % 17.15 % 8.88 % 55.46 % 61.97 %
Total Return
APUS ZTS TAK HLN TEVA NBIX
1 Month Return 30 % -3.83 % 0.67 % 1.66 % 11.59 % 6.75 %
3 Month Return 20799900 % -9.82 % -0.66 % -9.75 % 17.3 % 14.05 %
6 Month Return 0 % -8.1 % 0.6 % -3.35 % 22.05 % 28.1 %
9 Month Return 0 % -16.83 % 12.52 % 0.51 % 20.79 % 11.97 %
YTD Return 0 % -9.04 % 14.05 % 2.83 % -9.57 % 3.93 %
1 Year Return 0 % -22.44 % 2.72 % -6.66 % 8.26 % 16.05 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
APUS ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.26 % 4.36 % 0.02 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.89 % 2.03 % - 2.78 % 14.7 %
Dividend Per Share (TTM) - 1.93 % 196 % 0.06 % - -
Payout Ratio (TTM) - 32.08 % 226.17 % - - -
Growth
APUS ZTS TAK HLN TEVA NBIX
Asset Growth -96.91 % -5.7 % -9.55 %
Gross Profit Growth - 5.97 % 5.47 %
Revenue Growth - 7.45 % 4.4 %
Revenue 3 Year - 25.02 % 1.52 %
Revenue 5 Year - 35.03 % -5.5 %
Revenue 10 Year - 151.79 % -38.45 %
EBIT Growth -72.02 % 160.62 % -167.63 %
Net Income Growth -78.73 % -25.08 % -193.2 %
Net Income 3 Yeari Growth Per Share -35.45 % -54.31 % -482.97 %
Net Income 5 Yeari Growth Per Share -35.45 % 136.64 % -58.26 %
Net Income 10 Yeari Growth Per Share -35.45 % 172.34 % -140.46 %
Operating Income Growth -70.6 % 60.03 % -169.98 %
Operating Cash Flow Growth (CFG) -16.84 % 47.58 % -8.85 %
Operating 3 Year CFG 10.88 % -8.32 % 52.26 %
Operating 5 Year CFG 10.88 % 53.11 % 123.59 %
Operating 10 Year CFG 10.88 % 465.93 % -81.66 %
EPS Growth -77.78 % -25.78 % -190 %
EPS Diluted Growth -79.45 % -26.25 % -190 %
Book Value Per Share -4361.31 % -7.08 % -30.36 %
Share Holder 3 Year Equity Growth Per Share -469.48 % 18.85 % -49 %
Share Holder 5 Year Equity Growth Per Share -469.48 % 42.42 % -62.86 %
Share Holder 10 Year Equity Growth Per Share -469.48 % 217.07 % -82.6 %
Dividend Per Share Growth - 2.65 % -
Dividend 3 Year Growth Per Share - 3.86 % -
Dividend 5 Year Growth Per Share - 3.84 % -100 %
Dividend 10 Year Growth Per Share - 108.67 % -100 %
Debt Growth 123.63 % 4.59 % -10.29 %
Free Cash Flow Growth -16.84 % 263.47 % -11.05 %
Updated On 31 Dec 2024 31 Mar 2025 31 Dec 2024
Profitability
APUS ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM - 70.03 % 60.54 % 61.52 % 49.6 % 98.49 %
Return on Assets TTM -35.17 % 18.04 % 0.98 % 4.2 % -0.39 % 8.95 %
Return on Equity TTM -266.22 % 53.21 % 1.95 % 8.74 % -2.58 % 13.22 %
Return on Capital Employed TTM -37.01 % 31.67 % 3.43 % 7.74 % 3.16 % 14.8 %
Net Income Per EBT TTM 100 % 78.72 % 72.1 % 75.5 % 222.54 % 66.08 %
EBT Per Ebit TTM 102.91 % 94.26 % 46.84 % 86.58 % -7.94 % 106.48 %
EBIT Per Revenue TTM - 37.51 % 9.05 % 19.64 % 5.38 % 19.72 %
Cash Flow To Debt Ratio TTM -733.56 % 43.13 % 23.79 % - 7.93 % 129.2 %
Receivables Turnover TTM - 6.09 6.59 5.9 4.67 4.21
Payables Turnover TTM - 5.54 4.53 2.19 3.35 0.36
Inventory Turnover TTM - 1.15 1.54 3.63 2.4 0.66
Fixed Asset Turnover TTM - 244.46 % 229.02 % 584.75 % 321.73 % 429.78 %
Asset Turnover TTM - 64.82 % 31.99 % 32.73 % 41.43 % 64.53 %
Operating Cash Flow Per Share TTM -0.35 6.58 684.97 - 1.21 5.73
Free Cash Flow Per Share TTM -0.35 4.99 531.34 - 0.78 5.34
Cash Per Share TTM 84.24 % 322.4 % 26788.97 % 24.05 % 188.4 % 985.45 %
Operating Cash Flow Sales Ratio TTM - 31.21 % 23.92 % - 8.36 % 22.6 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 75.76 % 77.57 % - 64.03 % 93.2 %
Cash Flow Coverage Ratios TTM -733.56 % 43.13 % 23.79 % - 7.93 % 129.2 %
Price To Free Cash Flows Ratio TTM -7.13 30.6 8.44 - 25.45 27.05
Price To Operating Cash Flows Ratio TTM -5.88 23.28 6.56 - 16.3 25.16
Price Cash Flow Ratio TTM -5.88 23.28 6.56 - 16.3 25.16
Income Statement (TTM)
APUS ZTS TAK HLN TEVA NBIX
Revenue $0B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 0% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0B $3.87B $1210.51B $2.51B $0.78B $0.64B
Net Income $-0B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -0.11 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
APUS ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $5.39B $4517.23B $8.54B $16.3B $0.46B
Total Liabilities $0B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $-0B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0B $0B $10.8B $0.08B $0B $1.71B
Total Debt $0B $6.74B $5066.17B $10.1B $18.08B $0.46B
Total Assets $0B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
APUS ZTS TAK HLN TEVA NBIX
Net Income $-0B $2.5B $107.93B $1.44B $-1.96B $0.34B
Inventory $0B $-0.04B $-34.97B $0.22B $0.17B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0B $2.95B $1057.18B $2.3B $1.25B $0.6B
Capital Expenditure $0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.995
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 3.5
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 8.04
ALVOW Alvotech 0.96
AMPH Amphastar Pharmaceuticals, Inc. 27.8794
AMRX Amneal Pharmaceuticals, Inc. 9.92
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 97.78
AQST Aquestive Therapeutics, Inc. 4.97
ASRT Assertio Holdings, Inc. 0.8096
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 15.121
AYTU Aytu BioPharma, Inc. 2.4
ETFs With Exposure to APUS
Ticker ETF Name Weight Percentage Price
VXF Vanguard Extended Market Index Fund 0.00002 210
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0.00002 158.47
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0.00002 158.48
VEMPX Vanguard Extended Market Index InstlPlus 0.00002 391.07
Unlock